Metabolic dysfunction-associated steatotic liver disease in inflammatory bowel disease: prevalence, risk factors, pathophysiological pathways and clinical consequences DOI
Elena Grueso-Navarro, Alfredo J. Lucendo

Expert Review of Clinical Immunology, Год журнала: 2025, Номер unknown

Опубликована: Май 30, 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common comorbidity in patients with inflammatory bowel (IBD). This paper outlines pathophysiological aspects related to MASLD and IBD; describes epidemiological clues associated both diseases; analyzes risk factors contributing appearance progression IBD patients; reviews data on clinical consequences for this population; provides advice management of conditions. itself, especially Crohns' disease, a factor its cirrhosis, independent other cardiometabolic factors. Intestine-dependent mechanisms which contribute interplay classic metabolic include sarcopenia, phenotype, duration activity. Changes microbiota also deregulating gut-liver-axis these By contrast, therapies do not seem play relevant role developing MASLD; potential biologics novel small molecules changes requires further investigation. increases comorbidities, impairs outcomes mortality therefore, early detection priority populations. Individualized integrative required improve results.

Язык: Английский

Metabolic dysfunction-associated steatotic liver disease in inflammatory bowel disease: prevalence, risk factors, pathophysiological pathways and clinical consequences DOI
Elena Grueso-Navarro, Alfredo J. Lucendo

Expert Review of Clinical Immunology, Год журнала: 2025, Номер unknown

Опубликована: Май 30, 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common comorbidity in patients with inflammatory bowel (IBD). This paper outlines pathophysiological aspects related to MASLD and IBD; describes epidemiological clues associated both diseases; analyzes risk factors contributing appearance progression IBD patients; reviews data on clinical consequences for this population; provides advice management of conditions. itself, especially Crohns' disease, a factor its cirrhosis, independent other cardiometabolic factors. Intestine-dependent mechanisms which contribute interplay classic metabolic include sarcopenia, phenotype, duration activity. Changes microbiota also deregulating gut-liver-axis these By contrast, therapies do not seem play relevant role developing MASLD; potential biologics novel small molecules changes requires further investigation. increases comorbidities, impairs outcomes mortality therefore, early detection priority populations. Individualized integrative required improve results.

Язык: Английский

Процитировано

0